1,2,3,4,5,6-六氢吡咯并[3,4-C]吡咯 | 135325-06-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯啉
• 中文名称: 1,2,3,4,5,6-六氢吡咯并[3,4-C]吡咯
• 英文名称: 1,2,3,4,5,6-hexahydropyrrolo[3,4-c]pyrrole
• 英文别名: 3,7-diazabicyclo[3.3.0]oct-1(5)-ene
• CAS: 135325-06-3
• 化学式: C₆H₁₀N₂
• mdl: MFCD19159803
• 分子量: 110.159
• InChiKey: KGLCNBOXQUHILF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.9
• 重原子数：
  8
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.666
• 拓扑面积：
  24.1
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  二碳酸二叔丁酯 、 1,2,3,4,5,6-六氢吡咯并[3,4-C]吡咯 在 碳酸氢钠 作用下， 以 水 为溶剂， 以35 %的产率得到di-tert-butyl 4,6-dihydropyrrolo[3,4-c]pyrrole-2,5(1H,3H)-dicarboxylate
  参考文献：
  名称：

  [EN] PDE4B INHIBITOR AND USE THEREOF
  [FR] INHIBITEUR DE PDE4B ET SON UTILISATION
  [ZH] PDE4B抑制剂及其用途

  摘要：

  一种式I所示的化合物，其立体异构体或药学上可接受的盐，或含它们的药物组合物，及其作为PDE4B抑制剂在制备及治疗相关疾病的药物中的用途，式(I)所示中各基团如说明书之定义。

  公开号：

  WO2024032673A1

文献信息

• [EN] BICYCLIC AND BRIDGED NITROGEN HETEROCYCLES<br/>[FR] HÉTÉROCYCLES D'AZOTE BICYCLIQUES ET PONTÉS
  申请人：CHEMOCENTRYX INC

  公开号：WO2005084667A1

  公开（公告）日：2005-09-15

  Compounds are provided that act as potent modulators of one or more of the CCR1, CCR2 and CCR3 receptors. The compounds are generally fused-, spiro- or bridged-nitrogen heterocycles having an aryl and heteroaryl component and are useful in pharmaceutical compositions, methods for the treatment of CCR1-, CCR2- and/or CCR3-mediated diseases, and as controls in assays for the identification of competitive receptor antagonists for the above chemokine receptors.

  提供了作为CCR1、CCR2和CCR3受体中一个或多个的有效调节剂的化合物。这些化合物通常是融合的、螺环的或桥联的氮杂环，具有芳基和杂芳基组分，并且在制药组合物、用于治疗CCR1、CCR2和/或CCR3介导的疾病的方法以及作为上述趋化因子受体的竞争性受体拮抗剂的鉴定测定中的对照物中是有用的。
• 1,2,3,4-TETRAHYDROQUINOXALINE DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF
  申请人：Abbisko Therapeutics Co., Ltd.

  公开号：US20220009894A1

  公开（公告）日：2022-01-13

  A 1,2,3,4-tetrahydroquinoxaline derivative having a structure as represented by formula (I), preparation method therefor and application thereof. These compounds can be widely applied to preparation of drugs for treating one or more tumors, cancers, metabolic diseases, autoimmune diseases or disorders, and a new generation of RORγt agonist drugs is expected to be developed.

  一种具有如公式（I）所示结构的1,2,3,4-四氢喹喔啉衍生物，其制备方法及应用。这些化合物可以广泛应用于制备用于治疗一个或多个肿瘤、癌症、代谢性疾病、自身免疫疾病或紊乱的药物，预计将开发出新一代RORγt激动剂药物。
• [EN] INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X<br/>[FR] INHIBITION DE LA PEPTIDASE 9X SPÉCIFIQUE DE L'UBIQUITINE
  申请人：FORMA THERAPEUTICS INC

  公开号：WO2020139916A1

  公开（公告）日：2020-07-02

  The disclosure provides novel chemical compounds useful as inhibitors of ubiquitin specific peptidase 9X (USP9X). USP9X inhibiting compounds are useful in the treatment of disease and disorders associated with modulation of USP9X, such as cancer.

  该披露提供了一种新颖的化合物，可用作泛素特异性蛋白酶9X（USP9X）的抑制剂。抑制USP9X的化合物在治疗与调节USP9X相关的疾病和紊乱，如癌症，方面是有用的。
• FORMYLPYRIDINE DERIVATIVE HAVING FGFR4 INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR AND USE THEREOF
  申请人：Abbisko Therapeutics Co., Ltd.

  公开号：US20210130323A1

  公开（公告）日：2021-05-06

  Formylpyridine derivatives having FGFR4 inhibitory activities, a preparation method therefor and use thereof are described. In particular, the formylpyridine derivatives have a structure of formula (I), and the definition of each substituent in the formula are described in the description and claims. The series of compounds of the formula (I) have very strong inhibitory effects on FGFR4 kinases and very high selectivity, and can be widely used in the preparation of medicaments for treating cancers, particularly prostate cancer, liver cancer, pancreatic cancer, esophageal cancer, stomach cancer, lung cancer, breast cancer, ovarian cancer, colon cancer, skin cancer, neuroglioblastoma or rhabdomyosarcoma, and prospectively will be further developed to become a new generation of FGFR4 inhibitors.

  描述了具有FGFR4抑制活性的甲酰吡啶衍生物，其制备方法及用途。具体来说，这些甲酰吡啶衍生物具有式（I）的结构，该式中每个取代基的定义在描述和权利要求中有所描述。式（I）的一系列化合物对FGFR4激酶具有非常强的抑制作用和非常高的选择性，并可广泛用于制备用于治疗癌症的药物，特别是前列腺癌、肝癌、胰腺癌、食道癌、胃癌、肺癌、乳腺癌、卵巢癌、结肠癌、皮肤癌、神经胶质母细胞瘤或横纹肌肉瘤，并有望进一步发展成为新一代FGFR4抑制剂。
• [EN] 3- AND 6-QUINOLINES WITH N-ATTACHED HETEROCYCLIC CGRP RECEPTOR ANTAGONISTS<br/>[FR] 3- ET 6-QUINOLINES AVEC ANTAGONISTES DE RÉCEPTEURS DE PEPTIDES ASSOCIÉS AU GÈNE DE LA CALCITONINE HÉTÉROCYCLIQUE À N LIAISONS
  申请人：MERCK SHARP & DOHME

  公开号：WO2010021919A1

  公开（公告）日：2010-02-25

  Compounds of Formula (I): (where variables R1A, R1B, R2, R3, R4, A, and Z are as defined herein) which are useful as antagonists of CGRP receptors, and useful in the treatment or prevention of diseases in which CGRP receptors are involved, such as headache, and in particular migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP receptors are involved.

  公式（I）的化合物：（其中变量R1A、R1B、R2、R3、R4、A和Z的定义如下），这些化合物可用作CGRP受体的拮抗剂，并且在治疗或预防涉及CGRP受体的疾病方面具有用处，例如头痛，特别是偏头痛和集群头痛。本发明还涉及包含这些化合物的药物组合物以及这些化合物和组合物在预防或治疗涉及CGRP受体的这类疾病中的用途。